Sign up to save tools and stay up to date with the latest in AI
bg
bg
1

AI-driven drug discovery is poised to boom in 2024 | The AI Beat

Jan 08, 2024 - venturebeat.com
Isomorphic Labs, a unit of Alphabet, has announced two strategic research collaborations with Eli Lilly and Novartis for drug discovery, potentially worth a combined $3 billion. The partnerships include upfront payments and performance-based milestones. Isomorphic Labs, led by Google DeepMind founder Demis Hassabis, is building on the AlphaFold breakthrough, which has significantly advanced the understanding of biology and accelerated drug discovery.

In other AI-driven drug discovery news, Utah-based startup Recursion announced a collaboration with Nvidia and the launch of a new software platform for complex drug discovery tasks. Nvidia also announced a partnership with biotech leader Amgen. Meanwhile, professional service firms Deloitte and EY are entering the AI drug development field, with Deloitte launching Atlas AI, a drug discovery accelerator. TikTok parent company ByteDance is also recruiting talent for its AI for Drug Design and AI for Science teams.

Key takeaways:

  • Isomorphic Labs, a unit of Alphabet company, has announced two strategic research collaborations with Elli Lilly and Novartis for drug discovery, potentially worth a combined $3 billion.
  • Recursion, a Utah-based startup, announced a collaboration with Nvidia, which invested $50 million and provided access to its cloud-based tools for AI-powered drug discovery.
  • Professional services firms like Deloitte and EY are entering the AI drug development field, with EY partnering with BioPhy and Deloitte announcing Atlas AI, a drug discovery accelerator.
  • TikTok parent company ByteDance is also entering the AI drug discovery field, recruiting talent for its “AI for Drug Design” and “AI for Science” teams.
View Full Article

Comments (0)

Be the first to comment!